(Q38235601)

31 August 2017

title

Nemonoxacin: first global approval (English)

1 reference

31 August 2017

Raewyn M Poole

1

1 reference

31 August 2017

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

12

1 reference

31 August 2017

page(s)

1445-1453

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0270-0

31 August 2017

exact match

0 references

cites work

The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries' health care settings: a systematic review (1995 to 2012)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Improving known classes of antibiotics: an optimistic approach for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0270-0

Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25079302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0270-0

1 reference

Dimensions Publication ID

31 August 2017

1023088995

0 references

1 reference